Clinical Pharmacokinetics of Carbamazepine

Slides:



Advertisements
Similar presentations
Vigabatrin: Vigabatrin, the first 'designer drug' in the epilepsy field, is a vinyl-substituted analogue of GABA acts by inhibitng GABA transaminase.
Advertisements

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 24 Drugs for Epilepsy.
American Conference on Pharmacometics –San Diego, CA; April Population PK modeling incorporating enzyme induction mechanism to guide the design.
PHT 415 BASIC PHARMACOKINETICS Course Instructor:Prf. Dr. Hnaa elsaghir Assistant lecturers, Doaa elshora and eman elfakih Text: Hand book of basic pharmacokinetics,
PHCL-3720 Pharmacology II  Dr. William Messer  Department of Pharmacology  The University of Toledo  March 25, 2002.
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Nonlinear pharmacokinetics
Neuropharmacology of Antiepileptic Drugs
Prepared By Dr Shaheen Delivered By Dr Naser
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 16 Anticonvulsants.
DRUG INTERACTIONS IN EMERGENCY MEDICINE: AN OVERVIEW SCOTT LINSCOTT, MD UNIVERSITY OF UTAH SCHOOL OF MEDICINE.
Factors Affecting Drug Activity Chapter 11 Pages
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 11 Drug Therapy in Geriatric Patients.
Spotlight Case May 2007 Antiseizure Medication Disorder.
CLEARANCE (CL) describes the efficiency of irreversible elimination of a drug from the body by excretion of unchanged drug. Metabolic conversion of the.
Treatment. DEPENDS on the underlying cause Metabolic : correction Structural abnormality: seizure control + consider surgery Tumor Vascular Idiopathic.
Nonlinear Pharmacokinetics
Valproic Acid Software and Presentation by: Ted, Rob, Jeff, Cassie, Tristan, Korin, Ron, Gabe, Matt, Judith, Lindsay.
Anticonvulsant Pharmacokinetics Dennis Mungall, Pharm.D. Director, Virtual Education, NTPD Associate Professor Pharmacy Practice Ohio State University.
Problems of Polypharmacy
ANTIEPILEPTICS Dr: Samah Gaafar Hassan.  a periodic recurrence of seizures with or without convulsions.  A convulsion implies violent, involuntary contraction(s)
1 Applied Pharmacokinetics of Antiepileptic Drugs (AEDs) B. Gitanjali Gitanjali-21:
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
EPILEPSY BY Prof. AZZA El- Medany. ETIOLOGY Congenital defects Head injuries Trauma Hypoxia Infections Brain tumor Drug withdrawal.
CLINICAL PHARMACOKINETICS OF LIDOCAINE
DRUG INTERACTIONS. Definition „ pharmacological or clinical response to the administration of a drug combination is different from that anticipated from.
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Clinical Pharmacokinetics of Phenobarbital
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
Prof. Dr. Henny Lucida, Apt
Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects Linas Martinaitis Erasmus =)
Clinical Pharmacokinetics of Aminoglycosides
Therapeutic drug Monitoring
Clinical Pharmacokinetics of Procainamide Dr. Muslim Suardi Faculty of Pharmacy University of Andalas 2013.
Carbamazepine (Tegretol) Carbamazepine is one of the older drugs used for the treatment of epilepsy. It has a long history of effectiveness & safety. It.
Clinical Pharmacokinetics of PHENYTOIN & OTHER ANTIEPILEPTICS
Clinical Pharmacokinetic Equations and Calculations
Theophylline in broncial asthma. By:Heba Othman Essam El-Din Pharm –D4(2009).
Foundation Knowledge and Skills
Basic Concepts of Pharmacology © Paradigm Publishing, Inc.
Anxiolytic , Sedative and Hypnotic Drugs
Anticonvulsants: Phenytoin
Drugs used for anxiety and panic disorders
Drugs used for anxiety and panic disorders
Anti epileptic drugs.
Anticonvulsants By Alaina Darby.
ANTI EPILEPTIC DRUGS AFSAR FATHIMA M.Pharm.
Factors Affecting Drug Activity
Pharmacokinetics.
Cyclosporine.
Pharmacokinetics.
Pharmacokinetics.
Anticonvulsants: Valproic acid
Pharmacokinetics: Theophylline
Management Considerations in Epilepsy Among Long-Term Care Residents
School of Pharmacy, University of Nizwa
Clinical Pharmacokinetics
Anxiolytic, Sedative and Hypnotic Drugs
School of Pharmacy, University of Nizwa
School of Pharmacy, University of Nizwa
1 Concentration-time curve
Principle of Basic Clinical Pharmacokinetic parameters
Therapeutic Drug Monitoring chapter 1 part 1
Therapeutic Drug Monitoring
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
“Anti Epileptic Drugs II”
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
หัวหน้าหน่วยโรคภูมิแพ้ สถาบันสุขภาพเด็กแห่งชาติมหาราชินี
Presentation transcript:

Clinical Pharmacokinetics of Carbamazepine Dr. Muslim Suardi Faculty of Pharmacy University of Andalas 2013

Carbamazepine Partial or secondarily generalized seizures An iminostilbene derivative related to the tricyclic antidepressants that is used in the treatment of: Tonic-clonic (grand mal) Partial or secondarily generalized seizures

THERAPEUTIC & TOXIC CONCENTRATIONS Therapeutic range for CAR is 4–12 µg/mL for the treatment of seizures. CAR plasma protein binding (PPB) is quite variable among individuals because it is bound to both albumin & α1-acid glycoprotein (AGP). In normal patients, PPB is 75–80%, free fraction of drug of 20–25%.

CLINICAL MONITORING PARAMETERS Goal of anticonvulsants therapy is to reduce seizure frequency & maximize quality of life with a minimum of ADR. While it is desirable to entirely abolish all seizure episodes, it may not be possible to accomplish this in many patients.

CLINICAL MONITORING Patients should be monitored for conc-related side effects: Nausea, vomiting, lethargy, dizziness, Drowsiness, headache, blurred vision, Diplopia, unsteadiness, ataxia, Incoordination)

BASIC CLINICAL Pk PARAMETERS CAR is primarily eliminated by hepatic metabolism (99%) mainly via the CYP3A4 enzyme system. Altogether metabolites have been identified with CAR- 10, 11-epoxide being the major species. Epoxide metabolite is active & probably contributes to both the therapeutic & toxic side effects observed during therapy.

EFFECTS OF DISEASE STATES & CONDITIONS ON Pk & DOSING

DRUG INTERACTIONS CAR is a potent inducer of hepatic drug metabolizing enzyme systems Other antiepileptic drugs that have their Cl increased & Css decreased by CAR-related enzyme induction include: Felbamate, lamotrigine, PHENY, primidone, VAL Tiagabine, topiramate

DRUG INTERACTIONS CAR increases the Cl & decreases Css of many other drugs including: Oral contraceptives, Calcium channel blockers, Tricyclic antidepressants, Cyclosporin, Tacrolimus, Theophylline, Warfarin.

DRUG INTERACTIONS CAR Cl & CAR Css: PHENY & PHENO CAR CL & CAR Css: Cimetidine, macrolide antibiotics, azole antifungals, fluoxetine, fluvoxamine, nefazodone, cyclosporine, diltiazem, verapamil, indinavir, & ritonavir

DRUG INTERACTIONS Adm of single doses of CAR with grapefruit juice both AUC & Cmax of CAR by about 40%. Adm of single doses of CAR with grapefruit juice both AUC & Cmax of CAR by about 40%.

INITIAL DOSAGE DETERMINATION METHODS A simple partial seizures, LK, 51yo, 75-kg (5 ft 10 in) male who requires therapy with oral CAR. Normal liver function. Suggest an initial CAR dosage regimen designed to achieve a CAR Css equal to 6–8µg/mL.

Estimate CARBAMAZEPINE Dose According to Disease States & Condition Present in the Patient. The suggested initial dosage rate for immediate-release CAR tablets in an adult patient is 200 mg 2X daily (400 mg/d). This dose would be titrated upward in 200-mg increments every 2–3 weeks while monitoring for adverse & therapeutic effects.

Continued CAR Csr should also be measured if the patient experiences an exacerbation of their epilepsy, or if the patient develops potential signs or symptoms of CAR toxicity.

Continued The goal of therapy includes maximal suppression of seizures, avoidance of side effects, & a target drug range of 800–1200 mg/d. A SS trough total CAR Csr should be measured after SS is achieved in 2–3 weeks at the highest dosage rate attained.